In the aggregate, our in vitro findings warrant further preclinical studies of CRAd-IL24 to test its efficacy in murine ovarian cancer models to establish its potential utility for the virotherapy treatment of primary and advanced neoplastic diseases. This evidence concerns the gene IL24 and neoplasm.